Condition: Mesothelioma, Malignant · Mesothelioma, Malignant Pleural · Mesothelioma Malignant Advanced · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma. The aim of this study was to observe and evaluate the efficacy and safety of Sintilimab combined with Anlotinib hydrochloride and platinum-containing dual-agent chemotherapy as first-line therapy in malignant pleural mesothelioma.
This description comes directly from the study's public registry record.
Wang, MD,PhD · 8610-87788029 · zlhuxi@163.com
Duan, MD · 8610-87788029 · duanjianchun79@163.com
Always discuss trial participation with your own doctor first.
| Shanxi Provincial Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University | Taiyuan, Shanxi, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05188859